NASDAQ:ELGX - Endologix Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.75 -0.65 (-10.16 %)
(As of 06/21/2018 04:00 PM ET)
Previous Close$6.40
Today's Range$5.66 - $6.40
52-Week Range$3.75 - $6.72
Volume670,591 shs
Average Volume616,954 shs
Market Capitalization$527.59 million
P/E Ratio-11.96
Dividend YieldN/A
Beta0.44
Endologix logoEndologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. The company also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, it offers proximal aortic extensions and limb extensions which allows physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. The company offers its EVAR products under Ovation, Powerlink System, IntuiTrak, AFX, VELA Proximal Endograft brand names; and EVAS products under the Nellix EVAS system brand name. It sells its products through direct sales force, network of agents, and independent distributors or agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

Receive ELGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ELGX
CUSIP29266S10
Phone949-595-7200

Debt

Debt-to-Equity Ratio3.58
Current Ratio2.13
Quick Ratio1.37

Price-To-Earnings

Trailing P/E Ratio-11.96
Forward P/E Ratio-8.21
P/E GrowthN/A

Sales & Book Value

Annual Sales$181.16 million
Price / Sales2.67
Cash FlowN/A
Price / CashN/A
Book Value$0.90 per share
Price / Book6.39

Profitability

EPS (Most Recent Fiscal Year)($0.48)
Net Income$-66,400,000.00
Net Margins-35.86%
Return on Equity-47.01%
Return on Assets-9.92%

Miscellaneous

Employees675
Outstanding Shares84,010,000

Endologix (NASDAQ:ELGX) Frequently Asked Questions

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) announced its quarterly earnings data on Wednesday, May, 2nd. The medical instruments supplier reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.03. The medical instruments supplier had revenue of $42.28 million for the quarter, compared to analysts' expectations of $41.14 million. Endologix had a negative net margin of 35.86% and a negative return on equity of 47.01%. Endologix's revenue was down .8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.18) EPS. View Endologix's Earnings History.

When is Endologix's next earnings date?

Endologix is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Endologix.

What price target have analysts set for ELGX?

6 analysts have issued 12-month price targets for Endologix's stock. Their predictions range from $4.00 to $5.00. On average, they anticipate Endologix's share price to reach $4.75 in the next twelve months. View Analyst Ratings for Endologix.

What are Wall Street analysts saying about Endologix stock?

Here are some recent quotes from research analysts about Endologix stock:
  • 1. According to Zacks Investment Research, "Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. " (5/7/2018)
  • 2. Canaccord Genuity analysts commented, "Alimera reported 2Q17 Iluvien US sales of $8.1M which was above our estimate of." (8/4/2017)

Who are some of Endologix's key competitors?

Who are Endologix's key executives?

Endologix's management team includes the folowing people:
  • Mr. John Onopchenko, Chief Exec. Officer (Age 59)
  • Mr. Vaseem Mahboob, Chief Financial Officer (Age 49)
  • Dr. Michael V. Chobotov, Chief Technology Officer (Age 57)
  • Mr. Robert D. Mitchell, Consultant (Age 56)
  • Mr. Jeremy B. Hayden, Gen. Counsel (Age 48)

Has Endologix been receiving favorable news coverage?

Press coverage about ELGX stock has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Endologix earned a news impact score of 0.24 on Accern's scale. They also gave press coverage about the medical instruments supplier an impact score of 47.95 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Endologix's major shareholders?

Endologix's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.05%), Senzar Asset Management LLC (1.57%), Altrinsic Global Advisors LLC (1.23%), Cortina Asset Management LLC (0.76%), Schwab Charles Investment Management Inc. (0.45%) and C WorldWide Group Holding A S (0.35%). Company insiders that own Endologix stock include Christopher G Chavez, Dan Lemaitre, Guido J Neels, John D Mcdermott, Jose A Lima, Michael V Chobotov, Robert D Mitchell, Thomas F Zenty III and Vaseem Mahboob. View Institutional Ownership Trends for Endologix.

Which major investors are selling Endologix stock?

ELGX stock was sold by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, C WorldWide Group Holding A S, Wells Fargo & Company MN, Cortina Asset Management LLC and BlackRock Inc.. View Insider Buying and Selling for Endologix.

Which major investors are buying Endologix stock?

ELGX stock was acquired by a variety of institutional investors in the last quarter, including Altrinsic Global Advisors LLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Endologix stock in the last two years include Dan Lemaitre, Guido J Neels, John D Mcdermott, Robert D Mitchell, Thomas F Zenty III and Vaseem Mahboob. View Insider Buying and Selling for Endologix.

How do I buy shares of Endologix?

Shares of ELGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endologix's stock price today?

One share of ELGX stock can currently be purchased for approximately $5.75.

How big of a company is Endologix?

Endologix has a market capitalization of $527.59 million and generates $181.16 million in revenue each year. The medical instruments supplier earns $-66,400,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. Endologix employs 675 workers across the globe.

How can I contact Endologix?

Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected]


MarketBeat Community Rating for Endologix (ELGX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  355 (Vote Outperform)
Underperform Votes:  336 (Vote Underperform)
Total Votes:  691
MarketBeat's community ratings are surveys of what our community members think about Endologix and other stocks. Vote "Outperform" if you believe ELGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.